Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome

CD4+ lymphopaenia was associated with reduced OS in MBC patients regardless of the chemotherapy line. Decreased levels of plasmatic CCL22 may contribute to CD4+ lymphopaenia.